ArticleCureus2026
Efficacy of Biofeedback Therapy in Patients With Dyssynergic Defecation: A Hospital-Based Study in Eastern India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDyssynergic defecation, a disorder of the uncoordinated defecation process, is a common cause of chronic constipation. Biofeedback is a self-regulation technique where, based on visual feedback, patients learn coordination of the pelvic floor muscles. This study aims to evaluate the effectiveness of biofeedback therapy in patients with dyssynergic defecation.
methodsIn a prospective observational study carried out over a period of one year from June 2023 to May 2024 in patients diagnosed with dyssynergic defecation, biofeedback therapy sessions were given for 30 minutes to one hour per session every two weeks for a maximum of six sessions over three months. Improvements in the Bristol stool form scale, constipation scoring system, and/or quality of life (The Medical Outcomes Study Short Form-36 or SF-36) were used to assess the response to therapy.
resultsOf the total 83 participants, 49 (59.04%) were male, and the median age was 43 years. Type I dyssynergia was the most common type. Thirty (36.1%), 37 (44.6%), and nine (10.8%) participants had improvement in Bristol stool form, constipation severity score, and SF-36 score, respectively. Bristol type 3 was the most common stool form at the first visit, while type 4 was the predominant stool form at the last visit. An improvement in Bristol stool form was seen in 30 (36.1%) participants. The average constipation scores at the first and last visits were 15.7±1.86 and 13.4±2.79, respectively (P<0.05), with improvement seen in 37 (44.6%) participants. The average SF-36 scores at the initiation of therapy and the last visit were 47.7±4.15 and 48.08±3.84, respectively (P>0.05), with improvement seen in only nine (10.8%) participants. Post-biofeedback therapy, an improvement in either of the three parameters, i.e., Bristol stool form, constipation severity score, or SF-36 score, was seen in 59 (71.1%) participants, of whom 37 (62.71%) responded to the therapy with two sessions.
conclusionBiofeedback therapy is beneficial in patients with dyssynergic defecation, with significant improvements in stool form and constipation-related symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.